Preventative childhood vaccination to rabies

Bibliography

• Sudarshan MK, Madhusudana SN, Mahendra BJ, Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis 2007;11:29-35
   PubMed Web of Science ®Google Scholar
• Smith JS, Fishbein DB, Rupprecht CE, Unexplained rabies in three immigrants in the United States. A virologic investigation. N Engl J Med 1991;324:205-11
   PubMed Web of Science ®Google Scholar
• Wilde H. Failures of post-exposure rabies prophylaxis. Vaccine 2007;25:7605-9
   PubMed Web of Science ®Google Scholar
• Rupprecht CE, Hanlon CA, Slate D. Control and prevention of rabies in animals: paradigm shifts. Dev Biol 2006;125:103-11
   Google Scholar
• Chomel B, Chappuis G, Bullon F, Mass vaccination campaign against rabies: are dogs correctly protected? The Peruvian experience. Rev Infect Dis 1988;10(S4):S697-702
   PubMedGoogle Scholar
• Belotto AJ. Organization of mass vaccination for dog rabies in Brazil. Rev Infect Dis 1988;10(S4):S693-6
   PubMedGoogle Scholar
• Slate D, Algeo TP, Nelson KM, Oral rabies vaccination in north america: opportunities, complexities, and challenges. PLoS Negl Trop Dis 2009;3:e549
   PubMed Web of Science ®Google Scholar
• Smith GC, Thulke HH, Fooks AR, What is the future of wildlife rabies control in Europe? Dev Biol (Basel) 2008;131:283-9
   PubMedGoogle Scholar
• Noah DL, Drenzek CL, Smith JS, Epidemiology of human rabies in the United States, 1980 to 1996. Ann Intern Med 1998;128:922-30
   PubMed Web of Science ®Google Scholar
• Aguilar-Setien A, Leon YC, Tesoro EC, Vaccination of vampire bats using recombinant vaccinia-rabies virus. J Wildl Dis 2002;38:539-44
   PubMed Web of Science ®Google Scholar
• Delpietro HA, Russo RG. Ecological and epidemiologic aspects of the attacks by vampire bats and paralytic rabies in Argentina and analysis of the proposals carried out for their control. Rev Sci Tech 1996;15:971-84
   PubMed Web of Science ®Google Scholar
• Maier T, Schwarting A, Mauer D, Management and outcomes after multiple corneal and solid organ transplantations from a donor infected with rabies virus. Clin Infect Dis 2010;50:1112-19
   PubMed Web of Science ®Google Scholar
• Jackson AC. Therapy of rabies encephalitis. Biomedica 2009;29:169-76
   PubMed Web of Science ®Google Scholar
• Hemachudha T, Sunsaneewitayakul B, Desudchit T, Failure of therapeutic coma and ketamine for therapy of human rabies. J Neurovirol 2006;12:407-9
   PubMed Web of Science ®Google Scholar
• Willoughby RE Jr, Tieves KS, Hoffman GM, Survival after treatment of rabies with induction of coma. N Engl J Med 2005;352:2508-14
   PubMed Web of Science ®Google Scholar
• Faber M, Li J, Kean RB, Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc Natl Acad Sci USA 2009;106:11300-5
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang G, Wen Y, Intracerebral administration of recombinant rabies virus expressing GM-CSF prevents the development of rabies after infection with street virus. PLoS One 2011;6:e25414
   PubMed Web of Science ®Google Scholar
• Israsena N, Supavonwong P, Ratanasetyuth N, Inhibition of rabies virus replication by multiple artificial microRNAs. Antiviral Res 2009;84:76-83
   PubMed Web of Science ®Google Scholar
• Smith TG, Wu X, Franka R, Design of future rabies biologics and antiviral drugs. Adv Virus Res 2011;79:345-63
   PubMed Web of Science ®Google Scholar
• Khawplod P, Jaijaroensup W, Sawangvaree A, One clinic visit for pre-exposure rabies vaccination (a preliminary one year study). Vaccine 2011; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Malerczyk C, Briggs DJ, Dreesen DW, Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine. J Travel Med 2007;14:63-4
   PubMed Web of Science ®Google Scholar
• Khawplod P, Tangsupathus S, Jaijaroensup W, Immune response 8 years after single 0.1 mL intradermal dose of rabies vaccine. Vaccine 2012; In press
   Google Scholar
• Thraenhart O, Kreuzfelder E, Hillebrandt M, Long-term humoral and cellular immunity after vaccination with cell culture rabies vaccines in man. Clin Immunol Immunopathol 1994;71:287-92
   PubMedGoogle Scholar
• Suwansrinon K, Wilde H, Benjavongkulchai M, Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity. Vaccine 2006;24:3878-80
   PubMed Web of Science ®Google Scholar
• Shantavasinkul P, Tantawichien T, Jaijaroensup W, A 4 site, single visit intradermal postexposure prophylaxis regimen for previously vaccinated patients: experiences with > 5000 patients. Clin Infect Dis 2010;51:1070-2
   PubMed Web of Science ®Google Scholar
• Khawplod P, Wilde H, Sirikwin S, Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection. Vaccine 2006;24:3084-6
   PubMed Web of Science ®Google Scholar
• Shantavasinkul P, Tantawichien T, Wilde H, Postexposure rabies prophylaxis completed in 1 week: preliminary study. Clin Infect Dis 2010;50:56-60
   PubMed Web of Science ®Google Scholar
• WHO. Rabies vaccines. WHO position paper. Wkly Epidemiol Rec 2010;32:309-20
   Google Scholar
• Shwiff SA, Sterner RT, Jay MT, Direct and indirect costs of rabies exposure: a retrospective study in southern California (1998-2002). J Wildl Dis 2007;43:251-7
   PubMed Web of Science ®Google Scholar
• Lang J, Hoa DQ, Gioi NV, Immunogenicity and safety of low-dose intradermal rabies vaccination given during an expanded programme on immunization session in Viet Nam: results of a comparative randomized trial. Trans R Soc Trop Med Hyg 1999;93:208-13
   PubMed Web of Science ®Google Scholar
• Lang J, Rongrre N, Plotkin S, Booster vaccination at 1 year with a rabies vaccine associated with DTP-IPV in infants living in a rabies endemic country. J Trop Pediatr 1999;45:181-3
   PubMed Web of Science ®Google Scholar
• Vien NC, Feroldi E, Lang J. Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children. Trans R Soc Trop Med Hyg 2008;102:294-6
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Chantavanich P, Pasuralertsakul S, Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. Pediatr Infect Dis J 1998;17:1001-7
   PubMed Web of Science ®Google Scholar
• Chulasugandha P, Khawplod P, Havanond P, Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai children. Vaccine 2006;24:1478-82
   PubMed Web of Science ®Google Scholar
• Suss J, Sinnecker H. Immune reactions against rabies virus infection and vaccination. Exp Pathol 1991;42:1-9
   PubMedGoogle Scholar
• Xiang ZQ, Knowles BB, McCarrick JW, Immune effector mechanisms required for protection to rabies virus. Virology 1995;214:398-404
   PubMed Web of Science ®Google Scholar
• Theodorides J. Pasteur and rabies: the British connection. J R Soc Med 1989;82:488-90
   PubMed Web of Science ®Google Scholar
• Schnell MJ, Tan GS, Dietzschold B. The application of reverse genetics technology in the study of rabies virus (RV) pathogenesis and for the development of novel RV vaccines. J Neurovirol 2005;11:76-81
   PubMed Web of Science ®Google Scholar
• Dietzschold B, Wunner WH, Wiktor TJ, Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc Natl Acad Sci USA 1983;80:70-4
   PubMed Web of Science ®Google Scholar
• Faber M, Faber ML, Papaneri A, A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. J Virol 2005;79:14141-8
   PubMed Web of Science ®Google Scholar
• Coulon P, Rollin PE, Flamand A. Molecular basis of rabies virus virulence. II. Identification of a site on the CVS glycoprotein associated with virulence. J Gen Virol 1983;64:693-6
   PubMed Web of Science ®Google Scholar
• Faber M, Pulmanausahakul R, Nagao K, Identification of viral genomic elements responsible for rabies virus neuroinvasiveness. Proc Natl Acad Sci USA 2004;101:16328-32
   PubMed Web of Science ®Google Scholar
• Finke S, Conzelmann KK. Dissociation of rabies virus matrix protein functions in regulation of viral RNA synthesis and virus assembly. J Virol 2003;77:12074-82
   PubMed Web of Science ®Google Scholar
• Tan GS, Pruess MAR, Williams JC, The dynein light chain 8 binding motif of rabsi virus phosphoprotein promotes efficient viral transcription. Proc Natl Acad Sci USA 2007;104:7229-34
   PubMed Web of Science ®Google Scholar
• Schnell MJ, Mebatsion T, Conzelmann KK. Infectious rabies viruses from cloned cDNA. EMBO J 1994;13:4195-203
   PubMed Web of Science ®Google Scholar
• Cenna J, Hunter M, Tan GS, Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J Infect Dis 2009;200:1251-60
   PubMed Web of Science ®Google Scholar
• Faber M, Li J, Kean RB, Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc Natl Acad Sci USA 2009;106:11300-5
   PubMed Web of Science ®Google Scholar
• Ashraf S, Singh PK, Yadav DK, High level expression of surface glycoprotein of rabies virus in tobacco leaves and its immunoprotective activity in mice. J Biotechnol 2005;119:1-14
   PubMed Web of Science ®Google Scholar
• Loza-Rubio E, Rojas E, Gomez L, Development of an edible rabies vaccine in maize using the Vnukovo strain. Dev Biol (Basel) 2008;131:477-82
   PubMedGoogle Scholar
• Xiang ZQ, Spitalnik SL, Cheng J, Immune responses to nucleic acid vaccines to rabies virus. Virology 1995;209:569-79
   PubMed Web of Science ®Google Scholar
• Osorio JE, Tomlinson CC, Frank RS, Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine 1999;17:1109-16
   PubMed Web of Science ®Google Scholar
• Perrin P, Jacob Y, Aguilar-Setien A, Immunization of dogs with a DNA vaccine induces protection against rabies virus. Vaccine 1999;18:479-86
   PubMed Web of Science ®Google Scholar
• Lodmell DL, Ray NB, Parnell MJ, DNA immunization protects nonhuman primates against rabies virus. Nat Med 1998;4:949-52
   PubMed Web of Science ®Google Scholar
• Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 2011;23:421-9
   PubMed Web of Science ®Google Scholar
• Rupprecht CE, Hamir AN, Johnston DH, Efficacy of a vaccinia-rabies glycoprotein recombinant virus vaccine in raccoons (Procyon lotor). Rev Infect Dis 1988;10(S4):S803-9
   PubMedGoogle Scholar
• McGuill MW, Kreindel SM, DeMaria A Jr, Human contact with bait containing vaccine for control of rabies in wildlife. J Am Vet Med Assoc 1998;213:1413-17
   PubMed Web of Science ®Google Scholar
• Xiang ZQ, Yang Y, Wilson JM, A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 1996;219:220-7
   PubMed Web of Science ®Google Scholar
• Tatsis N, Fitzgerald JC, Reyes-Sandoval A, Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 2007;110:1916-23
   PubMed Web of Science ®Google Scholar
• Chen H, Xiang ZQ, Li Y, Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol 2010;84:10522-32
   PubMed Web of Science ®Google Scholar
• Ophorst OJ, Radosevic K, Havenga MJ, Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun 2006;74:313-20
   PubMed Web of Science ®Google Scholar
• Xiang Z, Gao G, Reyes-Sandoval A, Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 2002;76:2667-75
   PubMed Web of Science ®Google Scholar